Therefore, APP processing control by sodium-glucose cotransporter 2 inhibitors may play a pivotal role in disease-modifying therapy for Alzheimer’s disease but also diabetes mellitus. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.